This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia

This study has been terminated.
(difficulty with technical aspect of fMRI, resources to complete the study ran out)
Bristol-Myers Squibb
Information provided by (Responsible Party):
Erica Duncan, MD, Emory University Identifier:
First received: September 13, 2005
Last updated: November 13, 2013
Last verified: November 2013
The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.

Condition Intervention
Schizophrenia Other: fMRI Drug: Aripiprazole

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia

Resource links provided by NLM:

Further study details as provided by Erica Duncan, MD, Emory University:

Primary Outcome Measures:
  • BOLD Activation During fMRI Scanning During Performance of a Monetary Reward Task [ Time Frame: Baseline and 12 weeks ]
    fMRI BOLD activation during a reward task will be compared between schizophrenia subjects and controls at Baseline. Schizophrenia subjects will switch their baseline medication to aripiprazole and their BOLD activation during the reward task at Baseline will be compared to the endpoint scan.

Enrollment: 20
Study Start Date: April 2005
Study Completion Date: April 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: schizophrenia subjects
Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.
Other: fMRI
fMRI scanning during behavioral reward task
Drug: Aripiprazole
30 mg by mouth once daily

  Show Detailed Description


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Subjects with Schizophrenia:

Inclusion Criteria:

  • Diagnosed with schizophrenia
  • Male
  • Age 20-50
  • Right handed

Exclusion Criteria:

  • No current or past drug or alcohol problems (dependance or abuse)
  • Not color blind

Control Subjects:

Inclusion Criteria:

  • Male
  • Age 20-50
  • Right handed

Exclusion Criteria:

  • No current psychiatric problems
  • No current or past drug or alcohol problems
  • Not color blind
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00209027

United States, Georgia
Atlanta VA Medical Center
Decatur, Georgia, United States, 30033
Sponsors and Collaborators
Emory University
Bristol-Myers Squibb
Principal Investigator: Erica Duncan, MD Emory University/Atlanta VA Medical Center
  More Information

Friston KJ, Ashburner J, Frith CD, Poline J-B, Heather JD, Frackowiak RSJ (1995) Spatial registration and normalization of images. Hum Brain Mapp 2:1-25

Responsible Party: Erica Duncan, MD, Associate Professor, Emory University Identifier: NCT00209027     History of Changes
Other Study ID Numbers: IRB00024777
570-024 ( Other Identifier: Other )
Study First Received: September 13, 2005
Results First Received: April 13, 2012
Last Updated: November 13, 2013

Keywords provided by Erica Duncan, MD, Emory University:

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs processed this record on July 24, 2017